Er Therapeutics Stock Price To Earnings To Growth
| PNGM Stock | USD 0.0001 0.00 0.00% |
Er Therapeutics fundamentals help investors to digest information that contributes to Er Therapeutics' financial success or failures. It also enables traders to predict the movement of PNGM Stock. The fundamental analysis module provides a way to measure Er Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Er Therapeutics stock.
PNGM | Price To Earnings To Growth |
Er Therapeutics Company Price To Earnings To Growth Analysis
Er Therapeutics' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Er Therapeutics has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Metals & Mining sector and about the same as Materials (which currently averages 0.0) industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Equity Search Now
Equity SearchSearch for actively traded equities including funds and ETFs from over 30 global markets |
| All Next | Launch Module |
PNGM Fundamentals
| Return On Asset | -0.95 | ||||
| Current Valuation | 122.36 K | ||||
| Shares Outstanding | 58.26 M | ||||
| Price To Earning | (0.06) X | ||||
| Price To Book | 143,650 X | ||||
| Net Income | (426.95 K) | ||||
| Cash And Equivalents | 650 | ||||
| Total Debt | 48.49 K | ||||
| Current Ratio | 0.01 X | ||||
| Book Value Per Share | (0) X | ||||
| Cash Flow From Operations | (161.43 K) | ||||
| Beta | 10.4 | ||||
| Market Capitalization | 332.11 K | ||||
| Total Asset | 423.6 K | ||||
| Working Capital | (638 K) | ||||
| Current Asset | 7 K | ||||
| Current Liabilities | 645 K | ||||
| Net Asset | 423.6 K |
About Er Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Er Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Er Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Er Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Er Therapeutics Piotroski F Score and Er Therapeutics Altman Z Score analysis. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Diversified Metals & Mining space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Er Therapeutics. If investors know PNGM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Er Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.95) |
The market value of Er Therapeutics is measured differently than its book value, which is the value of PNGM that is recorded on the company's balance sheet. Investors also form their own opinion of Er Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Er Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Er Therapeutics' market value can be influenced by many factors that don't directly affect Er Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Er Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Er Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Er Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.